title: Molecules to selectively target receptors for treatment of pain and neurogenic inflammation.
abstract: Receptors that are involved in generation and transduction of pain signals attract much interest from the scientific and corporate communities. Good commercial prospects for successful development of effective analgesic drugs stimulate significantly the research. This article provides a brief overview of the key molecular targets, i.e. cell receptors, inhibition of which can lead to analgesia. Today transient receptor potential (TRP), purinergic (P2X) receptors and acidsensing ion channels (ASIC) are considered to be the most important proteins for perception of pain stimuli. These ionotropic receptors also participate in the development of inflammation; their hyperactivity leads to many pathological conditions and is closely associated with acute and inflammatory pain. Development of molecules capable to selectively modulate these receptors, their in vitro and in vivo effects, as well as perspectives for practical application described in patents and research articles are reviewed in this paper.
authors.affiliation: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho- Maklaya, 16/10, 117997 Moscow, Russia.
authors.forename: Yaroslav A
authors.initials: YA
authors.lastname: Andreev
authors.forename: Alexander A
authors.initials: AA
authors.lastname: Vassilevski
authors.forename: Sergey A
authors.initials: SA
authors.lastname: Kozlov
mesh_terms: D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D015195:Drug Design; D006801:Humans; D058990:Molecular Targeted Therapy; D020078:Neurogenic Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D058748:Pain Perception; D010330:Patents as Topic
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents